Sensitization to α-gal and omega-5-gliadin in patients with chronic urticaria: clinical implications and need for targeted testing.

Introduction: Chronic urticaria (CU) is defined as the presence of recurring hives and/or angioedema lasting more than 6 weeks. The precise impact of food allergies, particularly to galactose-α-1,3-galactose (α-gal) and omega-5-gliadin (O5G), on the development of CU is not well established.

Aim: The study examines the frequency of sensitisation to these allergens and their clinical significance in individuals with CU.

Predictive cytokines of omalizumab in the treatment of chronic spontaneous urticaria.

Background: Omalizumab, an anti-IgE biological agent, is commonly prescribed as a second-line therapy for Chronic Spontaneous Urticaria (CSU). However, there is a lack of biomarkers to predict which CSU patients will respond favorably to omalizumab.

Objective: Our study aims to identify cytokine markers associated with the efficacy of omalizumab in treating CSU.

Therapies for Chronic Spontaneous Urticaria: Present and Future Developments.

Chronic spontaneous urticaria (CSU) is a complex dermatological condition characterized by recurrent wheals and/or angioedema lasting for more than six weeks, significantly impairing patients' quality of life. According to European guidelines, the first step in treatment involves second-generation H1-antihistamines (sgAHs), which block peripheral H1 receptors to alleviate symptoms. In cases with inadequate responses, the dose of antihistamines can be increased by up to fourfold.

The association between baseline IgE level and urticaria control at six months of omalizumab treatment in chronic urticaria.

There is limited data on the use of baseline IgE level as a predictor of omalizumab response in chronic urticaria (CU). The aim of the present study was to determine if baseline serum total IgE level is associated with response at six months of standard-dose omalizumab. The study was designed as a retrospective, single-center, cohort survey.

Biological Effects and Clinical Application of the Anti-Immunoglobulin E Antibody.

Background: Immunoglobulin E (IgE) plays a pivotal role in the pathogenesis of allergic diseases by engaging with FcεRI and FcεRII receptors, triggering allergic responses. The development of anti-IgE antibodies, such as omalizumab, has introduced a targeted approach to allergy treatment by neutralizing free IgE and dampening the allergic cascade.

Summary: This review synthesizes the current understanding of IgE's role in allergic diseases and evaluates the clinical utility of omalizumab.

Erythema, localized edema and heat vs forearm perimeter increase. Time to revise the consensus recommendations on the vortex provocation test in vibratory urticaria-angioedema?

Background And Objective: Diagnosis of vibratory urticaria/angioedema is established after performing the vortex provocation test. There is current consensus on measuring the forearm perimeter after running such test to define a positive response to it.

Material And Method: We evaluated the frequency of prior symptoms following vibratory stimuli in volunteers using a questionnaire, response to the vortex provocation test in the same volunteers (increase in forearm perimeter, erythema, localized edema, heat, and pruritus), interrater reliability, and correlation between the scores obtained in the questionnaire and response to the test.

Severe chronic spontaneous urticaria responding and not responding to omalizumab: analysis of the prognostic value of known and novel in-vitro variables.

Chronic spontaneous urticaria (CSU) response to anti-IgE treatment can be rapid, late or absent. Recently, potential mechanisms of activation of mast cells alternative to FceRI, including mas-related G protein-coupled receptor X2 (MRGPRX2), activation of coagulation cascade, and activation of eosinophils have been described. We measured several potential in-vitro markers, including well-known MRGPRX2 activators, in sera of patients CSU both responding and not responding to omalizumab.

Efficacy evaluation of acupuncture combined with pricking blood therapy in the treatment of chronic spontaneous urticaria: a randomized controlled trial.

Objective: To assess the efficacy of combining acupuncture with pricking blood therapy to treat chronic spontaneous urticaria (CSU) and compare its outcomes with those of second-generation H1-antihistamines.

Methods: Seventy CSU patients were enrolled and randomly assigned to receive treatment with either oral loratadine tablets or a combination of acupuncture and pricking blood therapy (n=35 each). Evaluations were conducted at baseline, at the conclusion of the 4-week treatment period, and at the 4th and 8th weeks post-treatment time points.

Aquagenic urticaria: presentation, diagnosis and management.

Aquagenic urticaria, a rare dermatological condition characterised by urticarial eruptions following water contact, poses significant diagnostic and therapeutic challenges. This condition, although uncommon, necessitates heightened clinical awareness due to its substantial impact on the patient's quality of life. We present a comprehensive account of a paediatric case involving a girl in her mid-teens, who developed recurrent wheals post-exposure to water, independent of its temperature or source.

Bilastine Reimagined: A Comprehensive Exploration of Pruritus Management With a Novel Antihistamine.

Managing pruritic conditions is essential due to their significant impact on patients' quality of life. Chronic urticaria (CU), characterized by persistent itching and hives, severely affects daily activities and sleep. CU includes chronic inducible urticaria and chronic spontaneous urticaria, with the latter lacking identifiable triggers, making treatment especially challenging.

Eating increases disease activity in pediatric patients with symptomatic dermographism.

Symptomatic dermographism (SD) is the most common form of chronic inducible urticaria. SD disease activity increases with food intake in adult patients. Whether this is also so in children with SD is currently unknown.